TrialCancer science2015

Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer.

Naomi Kiyota et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.